LEADER 03853nam 22006614a 450 001 9910451880403321 005 20210528014121.0 010 $a1-280-94701-2 010 $a9786610947010 010 $a0-8135-3941-2 024 7 $a10.36019/9780813539416 035 $a(CKB)1000000000469403 035 $a(EBL)435065 035 $a(OCoLC)77560854 035 $a(SSID)ssj0000193594 035 $a(PQKBManifestationID)11172849 035 $a(PQKBTitleCode)TC0000193594 035 $a(PQKBWorkID)10226776 035 $a(PQKB)10304717 035 $a(MiAaPQ)EBC435065 035 $a(DE-B1597)530094 035 $a(DE-B1597)9780813539416 035 $a(Au-PeEL)EBL435065 035 $a(CaPaEBR)ebr10153082 035 $a(CaONFJC)MIL94701 035 $a(EXLCZ)991000000000469403 100 $a20050714d2006 ub 0 101 0 $aeng 135 $aurun#---|u||u 181 $ctxt 182 $cc 183 $acr 200 10$aLiving with cancer$b[electronic resource] $ea practical guide /$fDave Visel 210 $aNew Brunswick, N.J. $cRutgers University Press$dc2006 215 $a1 online resource (400 p.) 300 $aIncludes index. 311 0 $a0-8135-3819-X 327 $tFront matter --$tContents --$tForeword --$tPreface --$tAcknowledgments --$tQuick Starts --$tI. Introduction: Setting the Stage --$tII. Orientation: Some Preliminary Introductions and Suggestions --$tIII. Team Building: People Don?t Beat Cancer; Teams of People Do --$tIV. Supporting Resources: An Inventory and Evaluation of Available Tools --$tV. The Illness: Help a Patient Can Use, and Things a Patient Should Know, to Make the Best of This --$tVI. Related Issues: Topics You May Need to Know More About --$tVII. Relationships: Critical Elements of Patient-Partner Relationships --$tOne More Thing --$tReference Center --$tIndex --$tAbout the Author 330 $aIn this essential guide, Dave Visel draws on expertise hard-won during his wife?s battle with lymphoma. He provides an overview of the varieties of cancer and all the basic types of treatments available. Chapters dispel common myths associated with these treatments and provide tips on nutrition and physical fitness. Visel also moves beyond the hospital to provide information and strategies to help with the emotional, practical, and financial effects of a diagnosis. Cancer patients will find the tools they need to make well-informed decisions on questions ranging from the right time to tell coworkers to whether to travel for treatment. Because medical bankruptcies affect nearly two million Americans each year, Visel devotes several chapters to financial issues. He also addresses the effects of cancer on relationships, such as how to deal with a difficult parent or whether to reconcile with an estranged spouse. In addition, Living with Cancer provides a comprehensive overview of the most useful corporate, government, and non-profit resources available. Anyone looking for help in understanding the full range of personal, professional, and legal issues associated with cancer will welcome this book. As inspiring as it is informative, it is a survival guide in the truest sense. 606 $aCancer$vPopular works 606 $aCancer$xTreatment$vPopular works 606 $aCancer$xPsychological aspects 606 $aCancer$xPatients$xFamily relationships 608 $aElectronic books. 615 0$aCancer 615 0$aCancer$xTreatment 615 0$aCancer$xPsychological aspects. 615 0$aCancer$xPatients$xFamily relationships. 676 $a616.99/4 700 $aVisel$b Dave$f1938-$01049889 701 $aFisch$b Michael J$01049890 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910451880403321 996 $aLiving with cancer$92479236 997 $aUNINA LEADER 04631nam 2200457 450 001 9910484717803321 005 20210311104540.0 010 $a3-030-56905-5 024 7 $a10.1007/978-3-030-56905-1 035 $a(CKB)4100000011631365 035 $a(DE-He213)978-3-030-56905-1 035 $a(MiAaPQ)EBC6420702 035 $a(PPN)252517466 035 $a(EXLCZ)994100000011631365 100 $a20210311d2021 uy 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvances in host-directed therapies against tuberculosis /$fPetros C. Karakousis, Richard Hafner, Maria Laura Gennaro, editors 205 $a1st ed. 2021. 210 1$aCham, Switzerland :$cSpringer,$d[2021] 210 4$dİ2021 215 $a1 online resource (XIII, 332 p. 20 illus.) 311 $a3-030-56904-7 327 $aSection 1: Introduction -- Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis -- Section 2: Targeting immunometabolism -- Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism -- Chapter 3:The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells -- Chapter 4: HIF-1? as a potential therapeutic target for tuberculosis treatment -- Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis -- Section 3: Enhancing anti-mycobacterial mechanisms -- Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis -- Chapter 7: Metformin: a leading HDT candidate for TB -- Chapter 8: Statins as host-directed therapy for tuberculosis -- Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms -- Section 4: Targeting immune cells -- Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis -- Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma -- Chapter 12: Targeting suppressor T cells -- Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis -- Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis -- Chapter 15: Mucosal-associated invariant and V?9V?2 T cells -- Chapter 16: Airway epithelial cells.-Section 5: Preclinical models for assessing HDTs -- Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies -- Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis -- Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis -- Section 6: Clinical trials of HDTs and special considerations for study endpoints -- Chapter 20:Clinical trials of TB-HDT candidates -- Chapter 21:Outcomes for clinical trials of host-directed therapies for tuberculosis -- Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis. 330 $aThis book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective ? thus calling for pathway/factor enhancing drugs ? or maladaptive ? thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases. 606 $aImmunotherapy 615 0$aImmunotherapy. 676 $a616.079 702 $aHafner$b Richard 702 $aKarakousis$b Petros C. 702 $aGennaro$b Maria Laura 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910484717803321 996 $aAdvances in host-directed therapies against tuberculosis$92804770 997 $aUNINA